Astellas may not have wanted Ambit Biosciences ($AMBI) as a development partner, but fellow Japanese pharma Daiichi Sankyo wants it as an acquisition. Daiichi will snap up the once-dumped San Diego-based biotech for up to $410 billion in a move to beef up its oncology pipeline. With it comes quizartinib, a late-stage acute myeloid leukemia candidate. More